Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TPMT | P51580 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SELL | P14151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29738515 | 1.00 | TTR (0.56) | TTRTSHRTPMTCES2CES1 | |
| SCHEMBL15575090 | 0.89 | TTR (0.46) | TTRTSHRTPMTCES2CES1 | |
| SCHEMBL667661 | 0.89 | TTR (0.62) | TTRTSHRTPMTPLAULMNA | |
| SCHEMBL9693817 | 0.84 | CES2 (0.50) | TTRTSHRCES2CES1PLAU | |
| SCHEMBL221480 | 0.84 | CES2 (0.67) | TTRTSHRTPMTCES2CES1 | |
| SCHEMBL7922027 | 0.83 | CES2 (0.48) | TTRTSHRCES2CES1CA1 | |
| SCHEMBL791574 | 0.81 | TTR (0.54) | TTRTSHRTPMTPLAULMNA | |
| SCHEMBL29998931 | 0.81 | TTR (0.72) | TTRTSHRTPMTPLAULMNA | |
| SCHEMBL2684340 | 0.81 | TTR (0.72) | TTRTSHRTPMTPLAULMNA | |
| SCHEMBL3908489 | 0.81 | TTR (0.59) | TTRTSHRTPMTPLAULMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055016-B1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-04-29 | — | — | EP | disclosed |
| US-20240300965-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-12 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11999746-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-06-04 | — | — | US | disclosed |
| WO-2024059169-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-112272670-B | Di-ring derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2013013503-A1 | 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-8026262-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100069499-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2151431-A1 | AMIDE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2010-02-10 | — | — | EP | disclosed |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-22 | — | — | US | disclosed |
| US-7572820-B2 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-11 | — | — | US | disclosed |
| EP-2079466-A2 | SUBSTITUTED INDOLE COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008042571-A2 | SUBSTITUTED INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264482-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | TTR 4844/4885TSHR 1205/4885TPMT 2773/4885 |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | TTR 4844/4885TSHR 1205/4885TPMT 2773/4885 |
| US-20100069499-A1 | AMIDE COMPOUND AND USE THEREOF | CBR1, CBR3, GBA1 | TTR 2854/4885TSHR 163/4885TPMT 4672/4885 |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | USP9X, USP19, USP39 | TTR 3561/4885TSHR 4189/4885TPMT 1804/4885 |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | AR, NR5A1, NR3C2 | TTR 2914/4885TSHR 273/4885TPMT 3366/4885 |
| US-20240300965-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | TTR 2416/4885TSHR 4736/4885TPMT 3288/4885 |
| US-11999746-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | TTR 2416/4885TSHR 4736/4885TPMT 3288/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TTR 1481/4885TSHR 728/4885TPMT 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.